The FreeStyle Libre System will be available on the NHS starting November 1, pending approval from local health authorities.
This technology allows people with diabetes to monitor their blood sugar without finger pricks, a major shift in diabetes care.
Abbott, the manufacturer, announced that the flash glucose monitoring system has been added to the NHS Drug Tariff after approval by the NHS Business Services Authority. It will be reimbursed across England, Wales, Scotland, and Northern Ireland for people with type 1 and type 2 diabetes who use insulin intensively.
The system works through a small sensor, about the size of a £2 coin, worn on the back of the upper arm for up to 14 days. It automatically measures glucose levels, removing the need for regular finger pricks or manual calibration.
Clinical trials and real-world data from over 50,000 users show that people using the FreeStyle Libre scan their glucose levels about 15 times a day. Frequent scanning is linked to better glucose control, including fewer low and high blood sugar episodes and improved HbA1c levels.
Neil Harris, General Manager of Abbott UK Diabetes Care, called the system “game-changing technology.” He said it offers life-changing benefits for people who rely heavily on insulin and helps them lead healthier lives.
The system produces an Ambulatory Glucose Profile (AGP), a chart that shows glucose levels and trends over time. This helps users understand their condition better and allows doctors to make more informed treatment decisions.
Harris added that Abbott is rolling out education and support programs for patients and healthcare providers to maximize the benefits of this technology. They are also working closely with local health bodies to ensure access for people who need it.
Abbott manufactures the FreeStyle Libre sensor at its site in Witney, Oxfordshire. The company employs around 1,400 people in the UK and plans to add 150 more jobs due to the system’s global growth. The device is used by over 300,000 people worldwide and is available in more than 35 countries.
Chris Askew, Chief Executive of Diabetes UK, praised the announcement as a major step forward. He said flash glucose monitoring can free people from painful finger pricks and give them better control over their diabetes. This could help prevent serious long-term health issues.
Askew emphasized the need for fair access to this technology for all who can benefit. He called on local decision-makers to ensure people with diabetes can get the FreeStyle Libre wherever they live.
Related Topics:
